论文部分内容阅读
[目的]探讨赖氨肌醇维联合莫沙必利应用在功能性消化不良患儿中的临床效果及对胃肠动力的影响分析。[方法]对我院开展治疗的功能性消化不良患儿144例采用随机数字表法分为观察组和对照组,每组各72例,对照组给予莫沙必利治疗,观察组联合赖氨肌醇维治疗,比较2组临床疗效情况。[结果]观察组治疗总有效率为94.44%,对照组治疗总有效率为81.94%,组间比较差异有统计学意义(χ2=5.4025,P<0.05)。观察组治疗后上腹痛(1.01±0.13)分,厌食(1.13±0.21)分,嗳气(1.32±0.21)分,早饱(1.13±0.24)分,反酸(1.14±0.32)分,恶心呕吐(1.17±0.36)分,上述评分降低低于对照组,组间比较差异有统计学意义(t=14.1666、10.9072、10.6890、11.0841、10.3757、8.2219,P<0.05)。观察组治疗后5羟色胺(145.29±17.13)mg/L,生长抑素(3.22±0.62)mg/L;对照组治疗后5羟色胺(184.28±29.01)mg/L,生长抑素(4.61±1.04)mg/L,组间比较差异有统计学意义(t=9.8202、9.7412,P<0.05)。[结论]采用赖氨肌醇维联合莫沙必利应用在功能性消化不良患儿疗效可靠,能够有效地改善患儿临床症状积分,5羟色胺和生长抑素浓度降低,值得在临床上推广应用。
[Objective] To explore the clinical effect of LAM combined with mosapride on functional dyspepsia and its effect on gastrointestinal motility. [Methods] A total of 144 patients with dysfunctional dyspepsia who were treated in our hospital were divided into observation group and control group by random number table. Each group had 72 cases. The control group was given mosapride, and the observation group combined with lysine Inositol treatment, the clinical efficacy of two groups were compared. [Results] The total effective rate was 94.44% in the observation group and 81.94% in the control group. There was significant difference between the two groups (χ2 = 5.4025, P <0.05). In the observation group, the rates of upper abdominal pain (1.01 ± 0.13), anorexia (1.13 ± 0.21), belching (1.32 ± 0.21), early fullness (1.13 ± 0.24), acid reflux (1.14 ± 0.32), nausea and vomiting 1.17 ± 0.36) points, the above-mentioned scores were lower than the control group, the difference was statistically significant (t = 14.1666,10.9072,10.6890,11.0841,10.3757,8.2219, P <0.05). The levels of serotonin (145.29 ± 17.13) mg / L and somatostatin (3.22 ± 0.62) mg / L in the observation group after treatment were significantly lower than those in the control group (184.28 ± 29.01 mg / L, 4.61 ± 1.04 mg / mg / L, the difference between the two groups was statistically significant (t = 9.8202,9.7412, P <0.05). [Conclusion] The combination of lysostarein and mosapride in children with functional dyspepsia has reliable curative effect, which can effectively improve children’s clinical symptom scores, reduce the concentration of 5-hydroxytryptamine and somatostatin, and is worth popularizing in clinic .